Small molecule · developed by Biohaven
Opakalim (BHV-7000) is an investigational agent studied in focal epilepsy, given once daily at 50 mg or 75 mg in a blinded trial.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06309966 | Phase 2/3 | Focal Epilepsy | Active not recruiting | BHVN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Focal Epilepsy
Updated Nov 1, 2026. Something wrong or missing? Report it on the BHVN page.
See BHVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BHVN catalysts and pipeline →